A 40-year-old woman is found to have a 3 cm branch-duct intraductal papillary mucinous neoplasm (BD-IPMN) of the pancreatic body incidentally on CT. It has no 'worrisome features' or 'high-risk stigmata' on imaging. According to the 2023 European guidelines (European Study Group on Cystic Tumours of the Pancreas), what is the recommended management?
- A Surgical resection due to size >2 cm
- B Surveillance MRI/MRCP at 6 months, then annually if stable ✓
- C Endoscopic ultrasound-guided fine needle aspiration of all cysts >1 cm
- D Whipple's procedure regardless of features due to malignant potential
Explanation
The 2023 European guidelines for pancreatic cystic lesions recommend surveillance (MRI/MRCP) for BD-IPMN without high-risk stigmata (main pancreatic duct dilation ≥10 mm, mural nodule ≥5 mm, cytology positive) or worrisome features (cyst >3 cm, thickened walls, abrupt MPD caliber change, growth >5 mm/2 years). Without these features, surveillance at 6 months then annually is appropriate. Size alone (3 cm) is a 'worrisome feature' in some guidelines triggering EUS, but does not mandate immediate surgery without other high-risk features. Resection is for high-risk stigmata or confirmed malignancy.
Reference: Bailey & Love's Short Practice of Surgery, 27th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.